Personal Genomics: What Consumers and Investors Want to KnowWednesday, February 10, 2010, 6:00 p.m. - 8:30 p.m.
Koshland Theater, Oshman Family JCC, 3921 Fabian Way, Palo Alto (map)
Mapping the human genome was only the first step. With massive advances in the industrialization of genetic sequences, maps of our personal genomes are no longer strictly the domain of science fiction but, instead, a reality in our life times.
Admission: $60 at the door.
Sponsored by: Business Leadership Council (BLC).
RSVP: Business Leadership Council, 415.369.2875, blc@sfjcf.org
If you can't make it in person Palo Alto, join us virtually! We expect the Panel discussion to begin at 7:00 p.m PST:
Innovative companies are setting the tempo by providing consumers with powerful information concerning genealogy as well as risks and correlations to disease and other health related matters. Businesses are harnessing these biological advances in the forms of personalized diagnostic tests and treatment regimen.
- What do these trends portend for our society and relationships between physician and patients?
- Who will benefit from the massive databases of genetic information?
- What personal and professional responsibilities accompany the generation and dissemination of genetic information at the individual, family and social levels?
- What are the ethical and policy related implications of these revolutionary trends?
- Are you prepared to change your life or will having this information change it for you?
Panelists:
Michael Goldberg, Partner, Mohr Davidow Ventures
Michael joined MDV in 2005 and leads life science investments in the areas of molecular diagnostics, personalized medicine and wireless healthcare with particular interest in oncology, cardiology, immunology and neuroscience. He also leverages his knowledge of plant genetics and microbiology in support of the firm's energy investing.
Prior to joining MDV Michael was Managing Director of Jasper Capital and co-chair of the California Research and Cures Coalition ($3 billion Prop 71 California Stem Cell Research and Cures Initiative). He has held senior management and operations roles including serving as Chairman and CEO of OnCare, an oncology services company he founded in 1995.
Previously, Michael was Founder and Chief Executive Officer of Axion Inc., a cancer-focused healthcare service company he started in 1987 and sold to Bristol-Myers Squibb in 1996. Prior to his tenure with Axion, Michael was a member of the Operating Committee and Director of Corporate Development at Cetus Corporation (Novartis), one of the first biotech companies and the developer of PCR technology. He was also a co-founder of Agracetus, a joint venture with W.R. Grace & Co. (Monsanto), involved in plant genetic engineering. He was responsible for the commercialization of the company's agricultural technology.
Michael serves as a board member of the California Institute for Regenerative Medicine and of the Western Association of Venture Capitalists. He is also on the advisory councils of the Caltech Division of Biology, the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, and the Berkeley Center for Law and Technology. Michael is also an advisor to the UCSF Center for Translational and Policy Research on Personalized Medicine. He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation. Michael received a B.A. from Brandeis University and an M.B.A. from Stanford Graduate School of Business.
David Magnus, PhD, Chair, Program in Regenerative Medicine Sub-Committee on Bioethics and Conflict of Interest, Stanford University
Dr. Magnus is Professor of Pediatrics and Medicine at Stanford University, where he is Director of the Stanford Center for Biomedical Ethics and co-Chair of the Ethics Committee for the Stanford Hospital. In addition, he serves as Vice President and President-elect of the American Bioethics Program Directors, representing the leadership of 60 academic bioethics programs across North America. Dr. Magnus received his PhD in philosophy from Stanford University and has published articles on a range of topics in bioethics, particularly on issues concerning genetic technology, cloning, and stem cell research. He has served on the National Research Council Ad Hoc Committee on the Bioconfinement of Genetically Engineered Organisms, and as an “expert consultant” for the World Bank on food security and biotechnology and a consultant for the National Conference of State Legislators on cloning.
In 2003-2004, Dr. Magnus was a member of the Secretary of Agriculture’s Advisory Committee on Biotechnology in the 21st Century. He currently serves on the California Human Stem Cell Research Advisory Committee. He is the principle editor of a collection of essays entitled Who Owns Life? (2002) and his publications have appeared in Science, Nature Biotechnology, and the British Medical Journal. He serves as Associate Editor of the American Journal of Bioethics. He has appeared on many television shows including Good Morning America, CBS This Morning, FOX news Sunday, and ABC World News, several nationally syndicated radio shows and has been quoted in Time magazine, Newsweek, the Wall Street Journal, NY Times and USA Today among other publications. In addition to his scholarly work, he has published a number of editorial pieces in prominent newspapers.
Hugh Rienhoff, MD, Founder of MyDaughtersDNA.org
Dr. Rienhoff is a San Francisco Bay area physician and entrepreneur. He is the founder of MyDaughtersDNA.org, an organization dedicated to greater understanding of genetic conditions. He is the CEO of a privately-held biotechnology company and a member of the board of directors of several private companies in Boston and San Francisco.
During much of the 1990s, Dr. Rienhoff was a partner directing biotechnology investments at the venture firm New Enterprise Associates. He was a founding director of such companies as Healtheon/WebMD (HLTH) and Aurora Biosciences (ABSC). In 1998, he founded DNA Sciences (originally Kiva Genetics), a diagnostic company focused on genetic discoveries and served as its Chairman and CEO for four years. Dr.Rienhoff has served as a director on the boards of many public and private companies.
Dr. Rienhoff is an Adjunct Scientist at the Children’s Hospital Oakland Research Institute and is a Visiting Scholar at the University of California at Berkeley. He trained in mathematics, medicine, and genetics at Harvard University, Johns Hopkins University, and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received a Doctor of Medicine degree from Johns Hopkins University School of Medicine and a Bachelor of Arts degree in biology and English literature from Williams College.
Anne Wojcicki, Co-Founder, 23 and Me
Anne brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing world with the hope that she could have a positive impact on research and medicine through 23andMe. From her vantage point, Anne saw a need for creating a way to generate more information - especially more personalized information - so that commercial and academic researchers could better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information, 23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the public. (Plus, getting access to her own genetic information and understanding it has always been one of Anne's ambitions.) Anne graduated from Yale University with a B.S. in biology.
Moderator:
Robert Blum, President and Chief Executive Officer, Cytokinetics and Chair, Business Leadership Council of the Jewish Community Federation
Before assuming the role of President and CEO, Robert held senior level positions at Cytokinetics overseeing research and development, finance, corporate development, legal, commercial operations and business development since taking part in the launch of company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. Previously, he performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation from 1981.
Robert serves on the Board of BayBio and is on the faculty at the Center for BioEntrepreneurship at UC San Francisco where he has taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry.
Robert serves on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools designed to further science education and exploration in the spirit of repairing the world. Robert serves on the Board of the Jewish Community Federation of San Francisco and founded and chairs its Business Leadership Council. He has also served on the boards of San Francisco's Contemporary Jewish Museum and the Anti-Defamation League. He was recently named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. Robert received B.A. degrees in human biology and economics from Stanford University and an M.B.A. from Harvard Business School.
Bring your laptop to participate in the back channel discussion with free Wi-Fi.
View all events in the JCF calendar
|
